# Cue Biopharma, Inc.: overview CUE · Nasdaq · CIK 1645460 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/cue.md) · [Financials](/companies/cue/financials.md) · [Filings](/companies/cue/filings.md) · [Insiders](/companies/cue/insiders.md) Latest reported revenue: [$7.9m](/filings/0001193125-26-352128.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Aug 14, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001193125-26-352128). ## Last eight quarters | Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3.3](/filings/0001193125-25-277466.md) | [1.6 d](/filings/0001193125-26-108287.md) | [0.4](/filings/0001193125-26-224091.md) | [3.0](/filings/0001193125-26-352128.md) | [2.1](/filings/0001193125-25-277466.md) | [21.9 d](/filings/0001193125-26-108287.md) | [5.7](/filings/0001193125-26-224091.md) | [7.9](/filings/0001193125-26-352128.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(264.2%)](/filings/0001193125-25-277466.md) | [(611.2%) d](/filings/0001193125-26-108287.md) | [(2921.4%)](/filings/0001193125-26-224091.md) | [(292.3%)](/filings/0001193125-26-352128.md) | [(353.4%)](/filings/0001193125-25-277466.md) | [9.0% d](/filings/0001193125-26-108287.md) | [(94.1%)](/filings/0001193125-26-224091.md) | [(1113.3%)](/filings/0001193125-26-352128.md) | | Net margin | % | [(259.6%)](/filings/0001193125-25-277466.md) | [(602.5%) d](/filings/0001193125-26-108287.md) | [(2911.4%)](/filings/0001193125-26-224091.md) | [(287.1%)](/filings/0001193125-26-352128.md) | [(346.6%)](/filings/0001193125-25-277466.md) | [7.2% d](/filings/0001193125-26-108287.md) | [(91.1%)](/filings/0001193125-26-224091.md) | [(1943.2%)](/filings/0001193125-26-352128.md) | | Diluted EPS | $ per share | [(0.17)](/filings/0001193125-25-277466.md) | not reported | [(4.95)](/filings/0001193125-26-224091.md) | [(2.67)](/filings/0001193125-26-352128.md) | [(0.07)](/filings/0001193125-25-277466.md) | not reported | [(1.08)](/filings/0001193125-26-224091.md) | [(24.14)](/filings/0001193125-26-352128.md) | | Free cash flow | $m | [(7.5) d](/filings/0001193125-25-277466.md) | [(9.0) d](/filings/0001193125-26-108287.md) | [(8.3)](/filings/0001193125-26-224091.md) | [(3.4) d](/filings/0001193125-26-352128.md) | [(9.0) d](/filings/0001193125-25-277466.md) | [(1.1) d](/filings/0001193125-26-108287.md) | [(11.1)](/filings/0001193125-26-224091.md) | [(29.0) d](/filings/0001193125-26-352128.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [14.9](/filings/0000950170-23-008927.md) | [1.2](/filings/0000950170-24-038059.md) | [5.5](/filings/0000950170-25-047677.md) | [9.3](/filings/0001193125-26-108287.md) | [27.5](/filings/0001193125-26-108287.md) | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | [(292.6%)](/filings/0000950170-23-008927.md) | [(4275.1%)](/filings/0000950170-24-038059.md) | [(949.9%)](/filings/0000950170-25-047677.md) | [(446.9%)](/filings/0001193125-26-108287.md) | [(96.7%)](/filings/0001193125-26-108287.md) | | Net margin | % | [(295.6%)](/filings/0000950170-23-008927.md) | [(4257.8%)](/filings/0000950170-24-038059.md) | [(924.1%)](/filings/0000950170-25-047677.md) | [(438.0%)](/filings/0001193125-26-108287.md) | [(96.9%)](/filings/0001193125-26-108287.md) | | Diluted EPS | $ per share | [(1.41)](/filings/0000950170-23-008927.md) | [(1.49)](/filings/0000950170-24-038059.md) | [(1.11)](/filings/0000950170-25-047677.md) | [(0.72)](/filings/0001193125-26-108287.md) | [(0.28)](/filings/0001193125-26-108287.md) | | Free cash flow | $m | [(39.8)](/filings/0000950170-23-008927.md) | [(42.0)](/filings/0000950170-24-038059.md) | [(40.0)](/filings/0000950170-25-047677.md) | [(36.4)](/filings/0001193125-26-108287.md) | [(21.9)](/filings/0001193125-26-108287.md) | - Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/cue/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [Bleichroeder LP](/funds/1781002.md) | 2026-06-30 | $11.7m | 370,682 | | New +370,682 | | [Driehaus Capital Management LLC](/funds/938206.md) | 2026-06-30 | $9.2m | 292,144 | | New +292,144 | | [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $5.1m | 161,700 | | New +161,700 | | [Ikarian Capital, LLC](/funds/1778253.md) | 2026-06-30 | $3.3m | 104,364 | | New +104,364 | | [Tetragon Partners GP Ltd](/funds/1515070.md) | 2026-06-30 | $3.0m | 93,819 | | New +93,819 | | [STEMPOINT CAPITAL LP](/funds/1952142.md) | 2026-06-30 | $2.1m | 66,995 | | New +66,995 | | [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.8m | 57,807 | | New +57,807 | | [ADAR1 Capital Management, LLC](/funds/1940272.md) | 2026-06-30 | $1.7m | 55,193 | | New +55,193 | | [Lion Point Capital, LP](/funds/1643354.md) | 2026-06-30 | $1.7m | 52,928 | | New +52,928 | | [Squadron Capital Management LLC](/funds/2050709.md) | 2026-06-30 | $1.6m | 50,000 | | New +50,000 | ## Recent filings [All 550 filings](/companies/cue/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-09-21 | 12:00 ET | [8-K](/filings/0001193125-26-396094.md) | 7.01 Regulation FD disclosure; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-396094 | | 2026-08-21 | 20:55 ET | [SCHEDULE 13D](/filings/0001725092-26-000015.md) | Ownership report, active investor | 0001725092-26-000015 | | 2026-08-14 | 20:01 ET | [10-Q](/filings/0001193125-26-352128.md) | Quarterly report, period 2026-06-30 | 0001193125-26-352128 | | 2026-08-14 | 20:00 ET | [8-K](/filings/0001193125-26-352126.md) | 2.02 Results of operations | 0001193125-26-352126 | | 2026-08-03 | 20:47 ET | [8-K](/filings/0001193125-26-330730.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-330730 | | 2026-07-10 | 21:29 ET | [8-K](/filings/0001193125-26-301052.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 5.02 Departure or appointment of officers or directors; 8.01 Other events; 9.01 Financial statements and exhibits | 0001193125-26-301052 | | 2026-06-03 | 20:16 ET | [8-K](/filings/0001193125-26-255479.md) | 5.02 Departure or appointment of officers or directors; 5.07 Shareholder vote results; 9.01 Financial statements and exhibits | 0001193125-26-255479 | | 2026-06-02 | 20:45 ET | [8-K](/filings/0001193125-26-253709.md) | 5.02 Departure or appointment of officers or directors; 8.01 Other events | 0001193125-26-253709 | | 2026-05-21 | 12:51 ET | [DEF 14A](/filings/0001193125-26-233369.md) | Proxy statement, period 2026-06-01 | 0001193125-26-233369 | | 2026-05-14 | 20:19 ET | [8-K](/filings/0001193125-26-224101.md) | 9.01 Financial statements and exhibits | 0001193125-26-224101 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001193125-26-108287.md), filed Mar 16, 2026. ## Forecast league Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/4b2edd78-3b28-4ec6-b35b-ed70dcc0d526) ## About the filer - CIK: 1645460 - Tickers: CUE - Exchange: Nasdaq - SIC code: 2834 Pharmaceutical Preparations - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.